Amneal Pharmaceuticals Inc. (AMRX)
Amneal Pharmaceuticals (AMRX) Surpasses Q3 Earnings and Revenue Estimates
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.19 per share a year ago.
Amneal (AMRX) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Evaluate the expected performance of Amneal (AMRX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
5 Stocks Backed by High Efficiency for Solid Gains Amid Volatility
Invest in stocks of AMRX, CRON, CSV, BFST and APH to tap their high-efficiency levels.
Earnings Preview: Amneal Pharmaceuticals (AMRX) Q3 Earnings Expected to Decline
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How to Find Great Cheap Stocks Under $10 to Buy in October
On top of their cheap price tags, Wall Street analysts are high on all of these stocks and their improving earnings outlooks earn them strong Zacks Ranks.
Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year?
Here is how Amneal Pharmaceuticals (AMRX) and Astrazeneca (AZN) have performed compared to their sector so far this year.
Amneal Stock Rises 29% in a Month on Upbeat Regulatory Updates
AMRX stock gains 29.3% in a month due to the FDA's approval of Parkinson's Disease drug, Crexont.
Despite Fast-paced Momentum, Amneal (AMRX) Is Still a Bargain Stock
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2024 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q2 2024 Earnings Conference Call August 9, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President & Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President & Chief Financial Officer Joe Renda - Senior Vice President & Chief Commercial Officer, Specialty Conference Call Participants David Amsellem - Piper Sandler Leszek Sulewski - Truist Securities Operator Good morning and welcome to the Amneal Pharmaceuticals Second Quarter 2024 Earnings Call. I'd now like to turn the call over to Amneal's Head of Investor Relations, Tony DiMeo.
Compared to Estimates, Amneal (AMRX) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AMNEAL PHARMACEUTICALS, INC. (AMRX) Soars to 52-Week High, Time to Cash Out?
Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Amneal Pharmaceuticals (AMRX) Beats Q2 Earnings and Revenue Estimates
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.19 per share a year ago.
